Novo Nordisk said it will cut the list prices in the U.S. of two of its insulin drugs, Tresiba (insulin degludec) and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026. Fiasp's price ...

Tresiba (insulin degludec ... Pharma's Taro unit has made a bid to acquire Canadian biotech Antibe, a developer of drugs for pain and inflammation. Join the conversation, on Tuesday 28th January ...

In particular, it will give Tresiba an edge over Lantus in a highly competitive market, where biosimilars are driving down prices of Sanofi’s drug. Tresiba was approved by the FDA in 2015 on the ...